A large, placebo-controlled study reported meaningful back pain relief and better sleep with a low-dose THC medication—without signs of dependency.

State health officials pulled back proposed fee increases for Oregon’s supervised psilocybin program after broad backlash, but funding questions and possible tax changes remain.

A science-forward explainer on cross-tolerance between LSD and DOI, how repeat dosing can blunt effects, and what careful timing means for patients and clinicians.

NORML reports a pediatric clinical trial found a plant-derived cannabis preparation was safe and effective for autism, with disease severity falling about 2 points on a 7‑point scale after eight weeks.

Psychedelic Science Review reports a rapid rise in psilocybin interest, with 100+ clinical trials since the early 2000s and recent studies signaling strong therapeutic potential.